MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$668,647
Free Cash flow
-$3,291,074
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses
    • Accounts and other receivables
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,366,082
-3,630,610
-3,137,466
-5,051,084
Depreciation and amortization
61,556
114,518
123,659
113,360
Stock-based compensation expense
784,941
14,340
66,119
67,132
Fair value adjustment on warrants
-
-
0
2,747,460
Accounts and other receivables
209,587
143,274
92,972
27,121
Inventory
4,491
24,339
18,314
-8,737
Prepaid expenses and other assets
-17,660
-40,002
59,729
60,037
Accounts payable
133,634
74,310
-178,860
-229,076
Accrued expenses
-614,354
310,857
733,442
-63,487
Unearned revenue
0
-11,265
4,490
13,511
Operating lease right-of-use asset
4,381
-28,221
-68
-307
Net cash used in operating activities
-3,201,104
-3,227,240
-2,559,563
-2,480,298
Purchase of property and equipment
89,970
5,663
1
-3,646
Net cash used in investing activities
-89,970
-5,663
-1
3,646
Proceeds from issuance of common stock from direct offering, net of underwriting discounts, commissions, and offering expenses of 511,448 in 2026 and 112,922 in 2025
2,688,552
-
1,800,000
6,473,180
Proceeds from exercise of warrants
-
-
285
3,255,166
Proceeds from issuance of convertible preferred stock
-
-
0
990,000
Payment of offering costs for financing activities
-
-
353,480
1,418,459
(payments) proceeds from loans payable
-
-
-45,375
-
Payment on loans payable
46,109
29,544
-
-101,156
Principal repayments on finance leases
20,016
77,174
73,074
58,031
Net cash provided by financing activities
2,622,427
-118,513
1,340,151
9,343,012
Net decrease in cash and cash equivalents
-668,647
-3,351,416
-1,219,413
6,866,360
Cash and cash equivalents at beginning of period
3,098,366
6,449,782
7,669,195
1,105,291
Cash and cash equivalents at end of period
2,429,719
3,098,366
6,449,782
7,669,195
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock from...$2,688,552 (-3.92%↓ Y/Y)Net cash provided byfinancing activities$2,622,427 (-35.26%↓ Y/Y)Canceled cashflow$66,125 Net decrease in cashand cash...-$668,647 (-121.07%↓ Y/Y)Canceled cashflow$2,622,427 Stock-based compensationexpense$784,941 (45.84%↑ Y/Y)Accounts payable$133,634 (-26.79%↓ Y/Y)Depreciation andamortization$61,556 (-77.02%↓ Y/Y)Prepaid expenses andother assets-$17,660 (40.55%↑ Y/Y)Payment on loans payable$46,109 (-59.18%↓ Y/Y)Principal repayments onfinance leases$20,016 (-89.64%↓ Y/Y)Net cash used inoperating activities-$3,201,104 (25.36%↑ Y/Y)Canceled cashflow$997,791 Net cash used ininvesting activities-$89,970 (-40.11%↓ Y/Y)Net loss-$3,366,082 (49.92%↑ Y/Y)Accrued expenses-$614,354 (-75.19%↓ Y/Y)Accounts and otherreceivables$209,587 (129.22%↑ Y/Y)Inventory$4,491 (-72.55%↓ Y/Y)Operating leaseright-of-use asset$4,381 (616.02%↑ Y/Y)Purchase of property andequipment$89,970 (40.11%↑ Y/Y)

bioAffinity Technologies, Inc. (BIAFW)

bioAffinity Technologies, Inc. (BIAFW)